ArticleBritish journal of cancer2006
Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications.British journal of cancer · 2024Article
- Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience · 2023Review
- Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?International journal of molecular sciences · 2023Review
- Investigating Cutaneous Squamous Cell CarcinomaFrontiers in medicine · 2022Review
- Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.International journal of molecular sciences · 2021Article
- A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing.International journal of molecular sciences · 2019Article
- TYRO3: A potential therapeutic target in cancer.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- Article
- Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines.Oncotarget · 2017Article
- Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis.Oncology letters · 2017Article
- Article
- MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.Scientific reports · 2017Article
- Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.Medical oncology (Northwood, London, England) · 2015Article
- The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Evolution of high mobility group nucleosome-binding proteins and its implications for vertebrate chromatin specialization.Molecular biology and evolution · 2015Article
- Axl as a mediator of cellular growth and survival.Oncotarget · 2014Review
- The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma.Oncogene · 2014Article
- The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.Annals of surgical oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The molecular mechanisms that underlie the development of squamous cell skin cancers (SSC) are poorly understood. We have used oligonucleotide microarrays to compare the differences in cellular gene expression between a series of keratinocyte cell that mimic disease progression with the aim of identifying genes that may potentially contribute towards squamous cell carcinoma (SCC) progression in vivo, and in particular to identify markers that may serve as potential therapeutic targets for SCC treatment. Gene expression differences were corroborated by polymerase chain reaction and Western blotting. We identified Axl, a receptor tyrosine kinase with transforming potential that has also been shown to have a role in cell survival, adhesion and chemotaxis, was upregulated in vitro in SCC-derived cells compared to premalignant cells. Extending the investigation to tumour biopsies showed that the Axl protein was overexpressed in vivo in a series of SCCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.